Brand name: Eviplera TM
Active ingredients: tenofovir disoproxil + emtricitabine + rilpivirine
What it is used for
EVIPLERA is indicated for the treatment of HIV infection in treatment-naïve adult patients with plasma HIV-1 RNA =< 100,000 copies/mL at the start of therapy. EVIPLERA is also indicated in certain virologically-suppressed (HIV-1 RNA <50 copies/mL) adult patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see CLINICAL TRIALS). Patients must not have a history of resistance to any of the components of EVIPLERA (tenofovir DF, emtricitabine or rilpivirine).
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 30 degrees Celsius
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Purplish-pink, capsule-shaped film-coated tablet; debossed with 'GSI' on one side, and plain faced on the other side
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient tenofovir disoproxil + emtricitabine + rilpivirine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems